Show simple item record

dc.contributor.authorGisselbrecht, C
dc.contributor.authorSchmitz, N
dc.contributor.authorMounier, N
dc.contributor.authorSingh Gill, D
dc.contributor.authorLinch, D
dc.contributor.authorTrneny, M
dc.contributor.authorBosly, A
dc.contributor.authorMilpied, N
dc.contributor.authorRadford, John A
dc.contributor.authorKetterer, N
dc.contributor.authorShpilberg, O
dc.contributor.authorDührsen, U
dc.contributor.authorHagberg, H
dc.contributor.authorMa, D
dc.contributor.authorViardot, A
dc.contributor.authorLowenthal, R
dc.contributor.authorBrière, J
dc.contributor.authorSalles, G
dc.contributor.authorMoskowitz, C
dc.contributor.authorGlass, B
dc.date.accessioned2012-12-28T16:00:53Z
dc.date.available2012-12-28T16:00:53Z
dc.date.issued2012-10-22
dc.identifier.citationRituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. 2012: J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid23091101
dc.identifier.doi10.1200/JCO.2012.41.9416
dc.identifier.urihttp://hdl.handle.net/10541/263682
dc.description.abstractPURPOSEThe standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODSIn total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. RESULTS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). CONCLUSIONIn relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.titleRituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma.en
dc.typeArticleen
dc.contributor.departmentChristian Gisselbrecht and Josette Brière, Hôpital Saint Louis, Paris;en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB
html.description.abstractPURPOSEThe standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODSIn total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. RESULTS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). CONCLUSIONIn relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.


This item appears in the following Collection(s)

Show simple item record